Joshua Richter, MD / Saad Z. Usmani, MD, MBA, FACP - Optimizing Patient Outcomes in Relapsed/Refractory Multiple Myeloma: The Role of Novel BCMA-Targeted Bispecific Antibodies

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

7 Day Ceasefire Iran Offer, Trump-Xi AI Rivalry, More 10 min · 25 Sep 2026 · Bloomberg News Now

#685 - Joey Diaz 1h 59m · 25 Sep 2026 · This Past Weekend w/ Theo Von

NPR News: 09-25-2026 1AM EDT 5 min · 25 Sep 2026 · NPR News Now

1AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

The Same Yesterday, Today, and Forever 6 min · 25 Sep 2026 · Things Unseen with Sinclair B. Ferguson

The killer driver and member of Cock-Wall gang who poured bleach on elderly woman 22 min · 25 Sep 2026 · Crime World

Report any issue

Source

Recorded19 Sep 2023

Publisherc.answersincme.com ↗

Handlerec:10296341

Show notes

Please visit answersincme.com/GQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss B-cell maturation antigen (BCMA)–targeted therapies in the treatment of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Identify where BCMA-targeted therapies fit into the current treatment paradigm of RRMM; Describe the clinical profiles of new and emerging BCMA-targeted bispecific antibodies in heavily treated RRMM; and Outline strategies to optimally incorporate novel BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in